US Stock Market Move | Hesai (HSAI.US) rose over 7%, with Q2 net profit increasing by 60% year-on-year.
On Thursday, Hesai (HSAI.US) rose more than 7%, closing at $19.15.
On Thursday, Hesai (HSAI.US) rose over 7%, reaching $19.15. Recently, the Hesai Group Sponsored ADR announced its unaudited financial data for the second quarter of 2026. In the second quarter, Hesai reported revenue of 860 million RMB and a GAAP net profit of 70.55 million RMB, a year-on-year increase of 60.0%; this marks the fifth consecutive quarter of GAAP profitability for Hesai. For the first time, the strategic growth initiatives (SGI business) contributed revenue, primarily due to early commercialization breakthroughs in the power module business.
The Hesai power module began contributing revenue in this quarter, with over 10,000 sets delivered as of the end of the second quarter. The products are expanding from dexterous hand modules to full-body joint modules. The Kosmo spatial intelligence platform has completed the delivery of its first batch of prototypes and received orders from several leading humanoid robotics companies, including Galaxy Universal, which is expected to begin contributing revenue in the third quarter. Based on the better-than-expected commercialization progress and market demand of the SGI business, Hesai has raised its full-year SGI revenue guidance for 2026 to between 200 million and 300 million RMB; SGI revenue is expected to reach approximately 700 million RMB by 2027 and achieve breakeven.
Related Articles

LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.

3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.
LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.

3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.

RECOMMEND





